Table 2.
Treatment modalities according to the frontline and subsequent treatments for patients with SAA and VSAA
| n = 280‡ | Frontline treatment, n (%) | Subsequent treatment†, n (%) | ||
|---|---|---|---|---|
| rATG ± CsA* | 143 (51.1) | rATG ± CsA | 20 (14.0) | |
| Anabolic steroids | 20 (14.0) | |||
| CsA-based | 5 (3.5) | |||
| Anabolic steroids | 102 (36.4) | rATG ± CsA | 9 (8.8) | |
| CsA-based | 1 (1.0) | |||
| CsA-based# | 12 (4.3) | rATG ± CsA | 1 (8.3) | |
| Anabolic steroids | 1 (8.3) | |||
| No specific treatment | 23 (8.2) | - | ||
‡Did not include 3 patients who underwent HSCT
*rATG ± CsA: rATG with or without CsA; rATG with CsA (n = 123); rATG without CsA (n = 20)
#CsA-based: CsA contained treatment without ATG
†Subjects without subsequent treatment were not included
rATG, rabbit anti-thymocyte globulin; CsA, cyclosporin A